Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Suresh Chenji"'
Autor:
Haeseong Park, Samuel J. Klempner, Joseph Chao, Zev A. Wainberg, Mariusz Lukanowski, Suresh Chenji, Shannon Bourke, Anindya Chatterjee, Sylvie Lorenzen
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal a
Externí odkaz:
https://doaj.org/article/59e432c3ca784666b4112b265980437e
Autor:
Edward B. Garon, Carla Visseren-Grul, Maria Teresa Rizzo, Tarun Puri, Suresh Chenji, Martin Reck
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionIn the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared with placebo plus docetaxel for treatment of metastat
Externí odkaz:
https://doaj.org/article/b54245a672d24f66a33952de0821e809
Autor:
MARGA GIMENEZ, KAMLESH KHUNTI, KRISTEN SYRING, LEVENIA A. BAKER, SURESH CHENJI, REBECCA J. THRELKELD, YU YAN, MUNEHIDE MATSUHISA
Publikováno v:
Diabetes. 71
Objective: To evaluate and compare the efficacy and safety of 3 ready-to-use glucagon treatments for severe hypoglycemia in adults and children with diabetes: Baqsimi (nasal glucagon) , Gvoke (glucagon injection) , and Zegalogue (dasiglucagon injecti
Publikováno v:
Diabetes Therapy
Introduction/aim Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of long-acting and short-acting insulin analogs. The primary objective of this study was to investigate the pharmacodynamic response of once-daily IDegAsp dosing i